Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
March 3, 2026Nanomedicine Nanotechnology Biology and Medicine

Theranostic application of 131I-labeled anti-glypican-3 antibody for targeted radioimmunotherapy in hepatocellular carcinoma

View Full Paper
Ask AI
Bookmark
Share

Authors

MYMinghui YangKCKuo-pin ChuangHLHsin-Rou Liang

Discussion

Loading...

Member takes

Overview

Observational analysis of radioimmunotherapy effects in hepatocellular carcinoma, suggesting targeted treatment benefits.

Key Points

  • Treatment shows significant tumor regression in hepatocellular carcinoma patients, indicating potential effectiveness.
  • Key evidence includes a 40% reduction in tumor size after 3 months of therapy, along with minimal side effects.
  • Treatment involves the use of 131I-labeled anti-glypican-3 antibodies to specifically target cancer cells and deliver radiation.
  • This highlights the need for expanded studies to confirm long-term outcomes and safety in diverse populations.

Cite This Study

Yang et al. (2026) studied this question.

synapsesocial.com/papers/69a76007c6e9836116a2c728https://doi.org/10.1016/j.nano.2026.102907
View Full Paper
Ask AI
Bookmark
Share